– UK, London – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Thomas Eldered to its Board of Directors as Chairman, succeeding Dr. Steve Chatfield who will remain on the Board of Directors.
“Thomas brings to Prokarium over 30 years’ leadership and executive experience in the biopharmaceutical industry, successfully leading biotech innovation from early-stage research through commercialization. Over the course of his career, he co-founded and managed Recipharm AB, growing it into one of the five largest CDMOs in the world. As President of Flerie Invest, he has invested in companies with ambitious science across the life science sector,” said CEO, Dr. Kristen Albright. “We are thrilled to have the opportunity to work closely with Thomas during the next phase of Prokarium’s development.”
About Thomas Eldered
Thomas Eldered is President of Flerie Invest, which finances venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges. In 1995, Thomas Eldered co-founded Recipharm AB and went on to serve as CEO, leading the company through a successful IPO in 2014. Recipharm AB remains among the top five CDMOs in the world and now includes around 30 manufacturing and development facilities in Europe, India, Israel, and North America. E
“I am honored to be joining Prokarium’s Board of Directors at this time,” said Thomas Eldered. “Prokarium has a compelling data set supporting the advancement of their lead microbial immunotherapy program and is aiming to shift the treatment paradigm for bladder cancer patients. The company is also developing an exciting next-generation Salmonella platform that will target a broad range of cancer indications as a monotherapy or in combination with other advanced immunotherapies.”
Thomas Eldered received his MSc in Industrial and Management Engineering at Linköping University.
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
Prokarium is based in London, UK.
For more information : https://www.prokarium.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.